
Opinion|Videos|April 28, 2025
Diagnostic Approach to ATTR-CM
Panelists discuss how early clinical suspicion, genetic testing, cardiac biomarkers, and imaging techniques are crucial for diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM), while also highlighting challenges such as common misdiagnoses and delayed diagnoses, which can significantly impact patient outcomes and quality of life.
Advertisement
Episodes in this series

Summary for Physicians: Diagnostic Approach and Challenges in ATTR-CM
Diagnostic Approach to ATTR-CM:
- Clinical suspicion: Early recognition is critical, particularly in patients with unexplained heart failure, arrhythmias, or extracardiac symptoms such as carpal tunnel syndrome, spinal stenosis, and trigger fingers.
- Genetic testing: Identifying mutations in the transthyretin (TTR) gene can confirm hereditary transthyretin amyloid cardiomyopathy (ATTR-CM).
- Cardiac biomarkers: Elevated NT-proBNP and cardiac troponins can suggest cardiac involvement.
- Echocardiography and cardiac MRI: These imaging techniques help identify signs of restrictive cardiomyopathy, abnormal left ventricular wall thickness, and amyloid deposits.
- Tissue biopsy: In some cases, a biopsy (eg, from fat or cardiac tissue) may be performed to confirm amyloid deposition through Congo red staining.
- Scintigraphy: Technetium-labeled imaging agents, such as bone scintigraphy, can be used to detect cardiac amyloid deposits.
Challenges in Diagnosing ATTR-CM:
- Common misdiagnoses and underdiagnosis: ATTR-CM is often misdiagnosed as other forms of heart failure or restrictive cardiomyopathy. It may be mistaken for conditions such as hypertension, coronary artery disease, or idiopathic heart failure, especially in older patients.
- Delayed diagnosis: The slow progression of symptoms and their overlap with more common conditions lead to a significant delay in diagnosis. This can result in advanced disease before appropriate treatment is initiated.
Impact on Patient’s Quality of Life:
- Delayed diagnosis: A late diagnosis can result in worsening heart failure, arrhythmias, and irreversible organ damage, leading to a poor prognosis and diminished quality of life.
- Symptoms: Progressive symptoms such as heart failure, arrhythmias, and extracardiac manifestations (eg, carpal tunnel syndrome, trigger fingers) can severely affect daily activities, mobility, and overall well-being.
- Psychological impact: The uncertainty due to delayed diagnosis can cause anxiety and frustration for both patients and caregivers.
Early and accurate diagnosis is essential to improving patient outcomes, providing appropriate treatments, and enhancing the patient’s quality of life.
Advertisement
Related to this article

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.
Advertisement
Advertisement
Trending on HCPLive
1
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
2
Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO
3
What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers
4
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
5

